WallStreetZenWallStreetZen

NASDAQ: LMAT
Lemaitre Vascular Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Lemaitre Vascular earnings were $45.2M for the trailing 12 months ending Mar 31, 2025, with 32% growth year over year. The latest LMAT earnings report on Mar 31, 2025 announced Q1 2025 earnings of $11.0M, down 1.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LMAT reported annual earnings of $44.0M, with 46.3% growth. The next LMAT earnings date is Jul 30, 2025.

LMAT past earnings growth

How has LMAT's earnings growth performed historically?

Company
32.03%
Industry
16.24%
Market
34%
LMAT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
LMAT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
LMAT's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

LMAT earnings history

Current Revenue
$226.3M
Current Earnings
$45.2M
Current Profit Margin
20%
LMAT's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

LMAT Return on Equity

Current Company
13.5%
Current Industry
9.7%
Current Market
31.5%
LMAT's Return on Equity (13.5%)... subscribe to Premium to read more.
High Return on Equity Performance

LMAT undefined

Current Company
9.8%
Current Industry
8%
LMAT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when LMAT announces earnings.

LMAT undefined

Current Company
11.26%
Current Industry
10.3%
LMAT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LMAT vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
LMAT$69.65M$45.16M+18.08%$2.02
ATRC-$11.59M-$38.18MN/A-$0.81
AZTA$21.77M-$65.36MN/A-$1.48
PLSE-$59.08M-$60.24MN/A-$0.98
BLFS-$2.50M-$10.41MN/A-$0.36
View Top Medical Stocks

LMAT earnings dates

Next earnings date
Jul 30, 2025

Lemaitre Vascular Earnings Reports & History FAQ

What were Lemaitre Vascular's earnings last quarter?

On LMAT's earnings call on Invalid Date, Lemaitre Vascular (NASDAQ: LMAT) reported Q1 2025 earnings per share (EPS) of $0.49, up 11.36% year over year. Total LMAT earnings for the quarter were $11.01 million. In the same quarter last year, Lemaitre Vascular's earnings per share (EPS) was $0.44.

If you're new to stock investing, here's how to buy Lemaitre Vascular stock.

When does Lemaitre Vascular report earnings?

The next LMAT earnings date is Invalid Date. Add LMAT to your watchlist to be reminded of Lemaitre Vascular's next earnings date.

What was LMAT's earnings growth in the past year?

As of Lemaitre Vascular's earnings date in Invalid Date, Lemaitre Vascular's earnings has grown 32.03% year over year. This is 15.79 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 16.24%. LMAT earnings in the past year totalled $45.16 million.

Is Lemaitre Vascular profitable or losing money?

As of the last Lemaitre Vascular earnings report, Lemaitre Vascular is currently profitable. Lemaitre Vascular's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $45.16 million, a 33.02% increase year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.